Pharmacometrics strategist
Bayer AG, Germany
Dr. Bart Ploeger studied pharmacy at Groningen University in the Netherlands. After obtaining his PharmD in 1996, he received his PhD at Utrecht University (the Netherlands) for a risk assessment of chronic liquorice intake using PBPK-PD modelling & simulation. Between 2000 and 2011, he worked as a (senior) consultant and, from 2005 onwards, as Chief Scientific Officer at LAP&P Consultants BV in Leiden, The Netherlands, a pharmacometric CRO for advanced PK-PD. From 2011 until the site closure at the end of 2012, Bart worked at AstraZeneca’s innovative medicine unit for the central nervous and pain disease area in Södertälje (Sweden) as team leader and principal scientist non-clinical Modeling & Simulation. Early 2013, Bart joined the Clinical Pharmacometric group as head Quantitative Pharmacology at Bayer AG in Berlin, Germany. Since end of 2015, he is, as a pharmacometric strategist, responsible to identify and promote quantitative approaches in oncology and women health drug development projects. His research focuses on translational PK-PD, optimization of clinical trial designs using clinical trial simulation and real world data approaches to inform drug research and development.
.png)